

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6589602

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	BIOGEN IDEC MA INC.	03/31/2011
RECEIVING PARTY DATA		
Name:	MILLENNIUM PHARMACEUTICALS, INC.	
Street Address:	40 LANDSDOWNE STREET	
City:	CAMBRIDGE	
State/Country:	MASSACHUSETTS	
Postal Code:	02139	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	8802657
CORRESPONDENCE DATA		
Fax Number:	(650)493-6811	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6504615211	
Email:	cricks@wsgr.com	
Correspondent Name:	CHRISTINE RICKS	
Address Line 1:	650 PAGE MILL ROAD	
Address Line 4:	PALO ALTO, CALIFORNIA 94304	
ATTORNEY DOCKET NUMBER:	57841-701.301	
NAME OF SUBMITTER:	CHRISTINE RICKS	
SIGNATURE:	/Christine Ricks/	
DATE SIGNED:	03/08/2021	
Total Attachments: 8		
source=57841-701.301 Biogen to Millennium#page1.tif		
source=57841-701.301 Biogen to Millennium#page2.tif		
source=57841-701.301 Biogen to Millennium#page3.tif		
source=57841-701.301 Biogen to Millennium#page4.tif		
source=57841-701.301 Biogen to Millennium#page5.tif		
source=57841-701.301 Biogen to Millennium#page6.tif		

source=57841-701.301 Biogen to Millennium#page7.tif

source=57841-701.301 Biogen to Millennium#page8.tif

ASSIGNMENT OF PATENTS

BIOGEN IDEC MA INC., a Massachusetts corporation, having a principal place of business at 14 Cambridge Center, Cambridge, MA ("Assignor"), hereby irrevocably sells, transfers, conveys and assigns to MILLENNIUM PHARMACEUTICALS, INC., a Delaware corporation, having a principal place of business at 40 Landsdowne Street, Cambridge, MA 02139 ("Assignee"), the entire right, title and interest for the United States of America and its territorial possessions and all other countries and patent regions, including all rights of priority and rights to recover for past infringement, in the inventions disclosed in the patents and patent applications identified on Schedule A, together with the entire right, title, and interest in and to all patents and patent applications identified on Schedule A, all divisional, continuation, continuation-in-part, reissue, reexamination, extension or other applications based in whole or in part thereon or which claim priority or are related by terminal disclaimer thereto or therefrom, and all Letters Patent of the United States and all other countries and patent regions worldwide which may or shall be granted on said inventions, or any parts thereof ("Assignment").

Assignor acknowledges having received consideration for this Assignment.

Assignor does hereby authorize and request the Commissioner of Patents and Trademarks of the United States, and the equivalent authority in each other country and patent region in the world, to issue such Letters Patent as shall be granted upon said inventions or applications based thereon to Assignee, its successors and assigns.

[Remainder of page left intentionally blank.]

Witness my hand and seal this 31st day of March, 2011.

BIOGEN IDEC MA INC.

By: Paul J. Clancy

Name: Paul J. Clancy

Title: Chief Financial Officer

COMMONWEALTH OF MASSACHUSETTS

County of MIDDLESEX

On this 31st day of March, 2011, before me, the undersigned notary public, personally appeared PAUL CLANCY, proved to me through satisfactory evidence of identification, which was PERSONAL KNOWLEDGE, to be the person whose name is signed on the preceding document, and acknowledged to me that he signed it voluntarily for its stated purpose.

[affix seal]

Notary Public

My commission expires

Michael B. Parran
MICHAEL B. PARRAN
Notary Public
Commonwealth of Massachusetts
My Commission Expires
October 12, 2012



PATENT

REEL: 027441 FRAME: 0956

PATENT


REEL: 055524 FRAME: 0528

[Signature page for MPI]

Assignee hereby accepts this Assignment.

Witness my hand and seal this 31st day of March, 2011.

MILLENNIUM PHARMACEUTICALS, INC.

By: 

Name: Todd Shegoc

Title: SVP Finance + CFO

COMMONWEALTH OF MASSACHUSETTS

County of Middlesex


On this 31st day of March, 2011, before me, the undersigned notary public, personally appeared Todd Shegoc, proved to me through satisfactory evidence of identification, which was personally known to me, to be the person whose name is signed on the preceding document, and acknowledged to me that he signed it voluntarily for its stated purpose.

[affix seal]

Jean L. Ernst

Notary Public

My commission expires:



SCHEDULE A

K-5

PATENT
REEL: 027441 FRAME: 0958
PATENT

REEL: 055524 FRAME: 0530

Country	Case Type	Status	Title	Filing Date	Application Number	Patent Number	Grant Date	Publication Number	Publication Date
AR	ORD	Published	Compounds Useful as RAF Kinase Inhibitors	27-Jun-08	P080102801			AR067354A1	7-Oct-09
AU	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	2008273002				
BR	PCT	Pending	Compounds Useful as RAF Kinase Inhibitors	30-Jun-08	P10813499-5				
CA	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	2693182				
CL	ORD	Pending	Compounds Useful as RAF Kinase Inhibitors	27-Jun-08	1933/2008				
CN	PCT	Published	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	20088002788.9			101784545	21-Jul-10
EP	PCT	Published	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	8772238.5			2167489	31-Mar-10
GC	ORD	Pending	Compounds Useful as RAF Kinase Inhibitors	27-Jun-08	11195				
HK	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	10107335.7				
ID	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	W-00 2009 03699				
IL	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	202385				
IN	PCT	Pending	Compounds Useful as RAF Kinase Inhibitors	30-Jun-08	613/DENLP/2010				
JP	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	2010-515219				
KR	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	10-2009-7027037				
MX	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	MX/a/2009/014276				
NZ	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	582352				
PH	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	1-2010-500014				
RU	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	2009149214				
SG	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	200908633-1				
TW	ORD	Published	Compounds Useful as RAF Kinase Inhibitors	27-Jun-08	97124450			200916467	16-Apr-09
UA	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	200913589				
US	PRO	Converted	Compounds Useful as RAF Kinase Inhibitors	29-Jun-07	60/947291				
US	ORD	Published	Compounds Useful as RAF Kinase Inhibitors	30-Jun-08	12/164762			2009-0036419	5-Feb-09

K-6

PATENT

REEL: 027441 FRAME: 0959

PATENT

REEL: 055524 FRAME: 0531

Country	Case Type	Status	Title	Filing Date	Application Number	Patent Number	Grant Date	Publication Number	Publication Date
VE	ORD	Pending	Compounds Useful as RAF Kinase Inhibitors	27-Jun-08	2008-001277				
WO	ORD	Converted	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	PCT/US2008/068762			WO2009/006389	8-Jan-09
ZA	PCT	Pending	Pyrimidine Derivatives Useful as RAF Kinase Inhibitors	30-Jun-08	2009/09223				
AU	PCT	Pending	Heterocyclic Compounds Useful as RAF Kinase Inhibitors	30-Jun-08	2008273017				
CA	PCT	Pending	Heterocyclic Compounds Useful as RAF Kinase Inhibitors	30-Jun-08	2694284				
CN	PCT	Published	Heterocyclic Compounds Useful as RAF Kinase Inhibitors	30-Jun-08	200830022610.4			101743242	16-Jun-10
EP	PCT	Published	Heterocyclic Compounds Useful as RAF Kinase Inhibitors	30-Jun-08	8781174.1			2167497	31-Mar-10
IN	PCT	Pending	Heterocyclic Compounds Useful as RAF Kinase Inhibitors	30-Jun-08	620/DLNP/2010				
JP	PCT	Pending	Heterocyclic Compounds Useful as RAF Kinase Inhibitors	30-Jun-08	2010-515223				
NZ	PCT	Pending	Heterocyclic Compounds Useful as RAF Kinase Inhibitors	30-Jun-08	582349				
US	PRO	Converted	Heterocyclic Compounds Useful as RAF Kinase Inhibitors	29-Jun-07	60/947319				
US	ORD	Published	Heterocyclic Compounds Useful as RAF Kinase Inhibitors	30-Jun-08	12/164905			2009-0005359	1-Jan-09
WO	ORD	Converted	Heterocyclic Compounds Useful as RAF Kinase Inhibitors	30-Jun-08	PCT/US2008/068789			2009/006404	8-Jan-09
US	PRO	Converted	Heterocyclic Compounds Useful as RAF Kinase Inhibitors	30-Dec-08	61/141561				
WO	ORD	Published	Heterocyclic Compounds Useful as RAF Kinase Inhibitors	30-Dec-09	PCT/US2009/069795			2010/078408	8-Jul-10
AU	PCT	Pending	Pyrido Pyrimidinones, Dihydro Pyrimido Pyrimidinones and Pteridinones Useful as RAF Kinase Inhibitors	12-Dec-05	2005316668				
CA	PCT	Pending	Pyrido Pyrimidinones, Dihydro Pyrimido Pyrimidinones and Pteridinones Useful as RAF Kinase Inhibitors	12-Dec-05	2590294				
EP	PCT	Published	Pyrido Pyrimidinones, Dihydro Pyrimido Pyrimidinones and Pteridinones Useful as RAF Kinase Inhibitors	12-Dec-05	5853671.5			1828186	5-Sep-07

K-7

PATENT
REEL: 027441 FRAME: 0960

PATENT
REEL: 055524 FRAME: 0532

Country	Case Type	Status	Title	Filing Date	Application Number	Patent Number	Grant Date	Publication Number	Publication Date
JP	PCT	Pending	Pyrido Pyrimidinones, Dihydro Pyrimido Pyrimidinones and Pteridines Useful as RAF Kinase Inhibitors	12-Dec-05	2007-545694				
US	PRO	Converted	Pyrido Pyrimidinones, Dihydro Pyrimido Pyrimidinones and Pteridines Useful as RAF Kinase Inhibitors	16-Dec-04	60/636740				
US	PRO	Converted	Pyrido Pyrimidinones, Dihydro Pyrimido Pyrimidinones and Pteridines Useful as RAF Kinase Inhibitors	13-Dec-04	60/635644				
US	ORD	Granted	Pyrido Pyrimidinones, Dihydro Pyrimido Pyrimidinones and Pteridines Useful as RAF Kinase Inhibitors	12-Dec-05	11/301311	7767687	3-Aug-10	2006-0211702	21-Sep-06
US	CON	Pending	Pyrido Pyrimidinones, Dihydro Pyrimido Pyrimidinones and Pteridines Useful as RAF Kinase Inhibitors	26-Jul-10	12/843 105				
WO	ORD	Converted	Pyrido Pyrimidinones, Dihydro Pyrimido Pyrimidinones and Pteridines Useful as RAF Kinase Inhibitors	12-Dec-05	PCT/US2005/044804			2006/065703	22-Jun-06

K-8

Program	Docket Number	Country	Case Type	Status	Title	Filing Date	Application Number	Publication Number	Publication Date
PDK	P0702	CN	PCT	Published	Pyridinonyl PDK1 Inhibitors	2-Jul-07	200780031180.80	CN101541783A	23-Sep-09
PDK	P0702	EP	PCT	Published	Pyridinonyl PDK1 Inhibitors	2-Jul-07	7810166.4	2038272	25-Mar-09
PDK	P0702	IN	PCT	Pending	Pyridinonyl PDK1 Inhibitors	2-Jul-07	5299/KOLNP/2008	2009-542684	3-Dec-09
PDK	P0702	JP	PCT	Published	Pyridinonyl PDK1 Inhibitors	2-Jul-07	2009-518343		
PDK	P0702	US	PRO	Converted	Pyridinonyl PDK1 Inhibitors	30-Jun-06	60/806414		
PDK	P0702	US	PRO	Converted	Pyridinonyl PDK1 Inhibitors	19-Mar-07	60/919057		
PDK	P0702	US	PCT	Published	Pyridinonyl PDK1 Inhibitors	2-Jul-07	12/307104	2010-0144730	10-Jun-10
PDK	P0702	WO	ORD	Converted	Pyridinonyl PDK1 Inhibitors	2-Jul-07	PCT/US2007/015397	WO2008/005457	10-Jan-08
PDK	P0817	AR	ORD	Pending	Heterocyclic Compounds Useful as PDK1 Inhibitors	6-Oct-10	P100103633		
PDK	P0817	TW	ORD	Pending	Heterocyclic Compounds Useful as PDK1 Inhibitors	6-Oct-10	099134073		
PDK	P0817	US	PRO	Converted	Heterocyclic Compounds Useful as PDK1 Inhibitors	6-Oct-09	61/249095		
PDK	P0817	VE	ORD	Pending	Heterocyclic Compounds Useful as PDK1 Inhibitors	6-Oct-10	2010-001560		
PDK	P0817	WO	ORD	Pending	Heterocyclic Compounds Useful as PDK1 Inhibitors	5-Oct-10	PCT/US2010/051517		

K-9

RECORDED: 12/23/2011

RECORDED: 03/08/2021

PATENT
REEL: 027441 FRAME: 0962
PATENT

REEL: 055524 FRAME: 0534